According to the agreement, Cytovance will lead the cell culture process optimization, recovery and purification development, CGMP manufacturing and also technical and regulatory support to facilitate Selexys’ clinical program. Anti-PSGL-1 mAb will be manufactured at Cytovance’s 44,000sqft production facility that was custom-designed for multi-product CGMP manufacturing and the company claims that the unit meets US and EU regulatory standards.
Scott Rollins, president and CEO of Selexys Pharmaceutical, said: “Our development and manufacturing collaboration extends our strategic partnership with Cytovance as they have demonstrated on time execution of our first antibody for sickle cell disease. We look forward to this continued alliance as we work together towards advancing this important therapy to patients who suffer from Crohn’s.”
Darren Head, president and CEO of Cytovance Biologics, said: “We are pleased that Selexys has once again chosen Cytovance to work in concert as their development and manufacturing partner. This agreement confirms our shared commitment to highlight the biotechnology life science sector in Oklahoma City and is a testament to our clients to provide unsurpassed quality and innovative technical experience to their most important assets.”
Cytovance Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its CGMP manufacturing services, the company offers process development, CGMP cell banking and support services from its Oklahoma City, Oklahoma facilities.